MapLight Therapeutics (MPLT) Accumulated Expenses (2024 - 2025)
MapLight Therapeutics recorded quarterly Accumulated Expenses of $4.8 million in Q4 2025, down 65.62% quarter-over-quarter from $14.0 million in Q3 2025, and down 51.67% year-over-year from $10.0 million in Q4 2024.
MapLight Therapeutics' Accumulated Expenses history runs 2 years deep, the most recent figure standing at $4.8 million for Q4 2025.
- In Q4 2025, Accumulated Expenses fell 51.67% year-over-year to $4.8 million; the TTM figure through Dec 2025 stood at $4.8 million (down 51.67% YoY), while the FY2025 annual figure was $4.8 million, down 51.67% from the prior year.
- Accumulated Expenses came in at $4.8 million for Q4 2025 at MapLight Therapeutics, down from $14.0 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $14.0 million in Q3 2025 to a low of $4.8 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.83 Mn |
| Sep 30, 2025 | 14.05 Mn |
| Dec 31, 2024 | 9.99 Mn |